<i>Pseudomonas aeruginosa</i>: new insights into pathogenesis and host defenses
Tóm tắt
Từ khóa
Tài liệu tham khảo
Afacan, 2012, Therapeutic potential of host defense peptides in antibiotic-resistant infections, Curr Pharm Des, 18, 807, 10.2174/138161212799277617
Arancibia, 2002, Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis, Arch Intern Med, 162, 1849, 10.1001/archinte.162.16.1849
Bagge, 2004, Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production, Antimicrob Agents Chemother, 48, 1175, 10.1128/AAC.48.4.1175-1187.2004
Bardoel, 2011, Pseudomonas evades immune recognition of flagellin in both mammals and plants, PLoS Pathog, 7, e1002206, 10.1371/journal.ppat.1002206
Bianchi, 2008, Impairment of apoptotic cell engulfment by pyocyanin, a toxic metabolite of Pseudomonas aeruginosa, Am J Respir Crit Care Med, 177, 35, 10.1164/rccm.200612-1804OC
Bjarnsholt, 2009, Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients, Pediatr Pulmonol, 44, 547, 10.1002/ppul.21011
Bjarnsholt, 2010, Interference of Pseudomonas aeruginosa signalling and biofilm formation for infection control, Expert Rev Mol Med, 12, e11, 10.1017/S1462399410001420
Blohmke, 2012, Atypical activation of the unfolded protein response in cystic fibrosis airway cells contributes to p38 MAPK-mediated innate immune responses, J Immunol, 189, 5467, 10.4049/jimmunol.1103661
Bragonzi, 2009, Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence, Am J Respir Crit Care Med, 180, 138, 10.1164/rccm.200812-1943OC
Breidenstein, 2011, Pseudomonas aeruginosa: all roads lead to resistance, Trends Microbiol, 8, 419, 10.1016/j.tim.2011.04.005
Brimer, 1998, Cloning and comparison of fliC genes and identification of glycosylation in the flagellin of Pseudomonas aeruginosa a-type strains, J Bacteriol, 180, 3209, 10.1128/JB.180.12.3209-3217.1998
Cheung, 2000, Role of pulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa, Infect Immun, 68, 4585, 10.1128/IAI.68.8.4585-4592.2000
Chroneos, 2010, Pulmonary surfactant: an immunological perspective, Cell Physiol Biochem, 25, 13, 10.1159/000272047
Cohen, 2012, Cystic fibrosis: a mucosal immunodeficiency syndrome, Nat Med, 18, 509, 10.1038/nm.2715
Cornelis, 2010, Iron uptake and metabolism in pseudomonads, Appl Microbiol Biotechnol, 86, 1637, 10.1007/s00253-010-2550-2
Craig, 2004, Type 4 pilus structure and bacterial pathogenicity, Nat Rev Microbiol, 2, 363, 10.1038/nrmicro885
Kievit, 2000, Bacterial quorum sensing in pathogenic relationships, Infect Immun, 68, 4839, 10.1128/IAI.68.9.4839-4849.2000
Deep, 2011, Quorum sensing and bacterial pathogenicity: from molecules to disease, J Lab Physicians, 3, 4, 10.4103/0974-2727.78553
Denning, 1998, Pseudomonas pyocyanin increases interleukin-8 expression by human airway epithelial cells, Infect Immun, 66, 5777, 10.1128/IAI.66.12.5777-5784.1998
Devine, 2003, Antimicrobial peptides in defence of the oral and respiratory tracts, Mol Immunol, 40, 431, 10.1016/S0161-5890(03)00162-7
Doring, 2007, A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients, P Natl Acad Sci USA, 104, 11020, 10.1073/pnas.0702403104
Du, 2010, Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1, Mol Cell Biol, 30, 3444, 10.1128/MCB.00813-09
Engel, 1998, Pseudomonas aeruginosa protease IV produces corneal damage and contributes to bacterial virulence, Invest Ophthalmol Vis Sci, 39, 662
Ernst, 1999, Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa, Science, 286, 1561, 10.1126/science.286.5444.1561
Ernst, 2006, The Pseudomonas aeruginosa lipid A deacylase: selection for expression and loss within the cystic fibrosis airway, J Bacteriol, 188, 191, 10.1128/JB.188.1.191-201.2006
Ernst, 2007, Unique lipid A modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis, J Infect Dis, 196, 1088, 10.1086/521367
Falagas, 2006, Toxicity of polymyxins: a systematic review of the evidence from old and recent studies, Crit Care, 10, R27, 10.1186/cc3995
Feldman, 1998, Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection, Infect Immun, 66, 43, 10.1128/IAI.66.1.43-51.1998
Fernandez, 2010, Adaptive resistance to the ‘last hope’ antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS, Antimicrob Agents Chemother, 54, 3372, 10.1128/AAC.00242-10
Flato, 1996, DNA adduct formation in the human nasal mucosa as a biomarker of exposure to environmental mutagens and carcinogens, Environ Health Perspect, 104, 471, 10.1289/ehp.96104s3471
Fleiszig, 2002, The pathogenesis of bacterial keratitis: studies with Pseudomonas aeruginosa, Clin Exp Optom, 85, 271, 10.1111/j.1444-0938.2002.tb03082.x
Fujimoto, 2002, Effects of Cl2MDP-encapsulating liposomes in a murine model of Pseudomonas aeruginosa-induced sepsis, J Liposome Res, 12, 239, 10.1081/LPR-120014760
Galperin, 2006, Structural classification of bacterial response regulators: diversity of output domains and domain combinations, J Bacteriol, 188, 4169, 10.1128/JB.01887-05
Gellatly, 2012, The Pseudomonas aeruginosa PhoP-PhoQ two-component regulatory system is induced upon interaction with epithelial cells and controls cytotoxicity and inflammation, Infect Immun, 80, 3122, 10.1128/IAI.00382-12
Gooderham, 2009, Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa, FEMS Microbiol Rev, 33, 279, 10.1111/j.1574-6976.2008.00135.x
Hall-Stoodley, 2009, Evolving concepts in biofilm infections, Cell Microbiol, 11, 1034, 10.1111/j.1462-5822.2009.01323.x
Hancock, 1983, Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains, Infect Immun, 42, 170, 10.1128/IAI.42.1.170-177.1983
Hancock, 2012, Modulating immunity as a therapy for bacterial infections, Nat Rev Microbiol, 10, 243, 10.1038/nrmicro2745
Hauser, 2009, The type 3 secretion system of Pseudomonas aeruginosa: infection by injection, Nat Rev Microbiol, 7, 654, 10.1038/nrmicro2199
Hayes, 2011, The cystic fibrosis neutrophil: a specialized yet potentially defective cell, Arch Immunol Ther Exp (Warsz), 59, 97, 10.1007/s00005-011-0113-6
Heeb, 2011, Quinolones: from antibiotics to autoinducers, FEMS Microbiol Rev, 35, 247, 10.1111/j.1574-6976.2010.00247.x
Hidron, 2008, NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007, Infect Control Hosp Epidemiol, 29, 996, 10.1086/591861
Hobden, 2002, Pseudomonas aeruginosa proteases and corneal virulence, DNA Cell Biol, 21, 391, 10.1089/10445490260099674
Hogardt, 2010, Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung, Int J Med Microbiol, 300, 557, 10.1016/j.ijmm.2010.08.008
Hogardt, 2007, Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis, J Infect Dis, 195, 70, 10.1086/509821
Holm, 1991, Inhibition of pulmonary surfactant function by phospholipases, J Appl Physiol, 71, 317, 10.1152/jappl.1991.71.1.317
Holt, 2008, Regulation of immunological homeostasis in the respiratory tract, Nat Rev Immunol, 8, 142, 10.1038/nri2236
Hurd, 2000, The impact of COPD on lung health worldwide: epidemiology and incidence, Chest, 117, 1S, 10.1378/chest.117.2_suppl.1S
Jimenez, 2012, The multiple signaling systems regulating virulence in Pseudomonas aeruginosa, Microbiol Mol Biol Rev, 76, 46, 10.1128/MMBR.05007-11
Johansen, 2008, Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients, J Cyst Fibros, 7, 391, 10.1016/j.jcf.2008.02.003
Jung, 2011, Histidine kinases and response regulators in networks, Curr Opin Microbiol, 15, 1
Kaplan, 2010, Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses, J Dent Res, 89, 205, 10.1177/0022034509359403
Kelly, 1989, Pseudomonas aeruginosa pili as ligands for nonopsonic phagocytosis by fibronectin-stimulated macrophages, Infect Immun, 57, 3841, 10.1128/IAI.57.12.3841-3845.1989
King, 2009, Lipopolysaccharide biosynthesis in Pseudomonas aeruginosa, Innate Immun, 15, 261, 10.1177/1753425909106436
Kipnis, 2006, Targeting mechanisms of Pseudomonas aeruginosa pathogenesis, Med Mal Infect, 36, 78, 10.1016/j.medmal.2005.10.007
Knight, 2003, The airway epithelium: structural and functional properties in health and disease, Respirology, 8, 432, 10.1046/j.1440-1843.2003.00493.x
Knowles, 2002, Mucus clearance as a primary innate defense mechanism for mammalian airways, J Clin Invest, 109, 571, 10.1172/JCI0215217
Kohler, 2000, Swarming of Pseudomonas aeruginosa is dependent on cell-to-cell signaling and requires flagella and pili, J Bacteriol, 182, 5990, 10.1128/JB.182.21.5990-5996.2000
Kooguchi, 1998, Role of alveolar macrophages in initiation and regulation of inflammation in Pseudomonas aeruginosa pneumonia, Infect Immun, 66, 3164, 10.1128/IAI.66.7.3164-3169.1998
Kuang, 2011, Pseudomonas aeruginosa elastase provides an escape from phagocytosis by degrading the pulmonary surfactant protein-A, PLoS ONE, 6, e27091, 10.1371/journal.pone.0027091
Laarman, 2012, Pseudomonas aeruginosa alkaline protease blocks complement activation via the classical and lectin pathways, J Immunol, 188, 386, 10.4049/jimmunol.1102162
Lam, 2011, Genetic and functional diversity of Pseudomonas aeruginosa lipopolysaccharide, Front Microbiol, 2, 1, 10.3389/fmicb.2011.00118
Lau, 2004, The role of pyocyanin in Pseudomonas aeruginosa infection, Trends Mol Med, 10, 599, 10.1016/j.molmed.2004.10.002
Lau, 2005, Pseudomonas aeruginosa OxyR is required for full virulence in rodent and insect models of infection and for resistance to human neutrophils, Infect Immun, 73, 2550, 10.1128/IAI.73.4.2550-2553.2005
Li, 1995, Response regulators CheB and CheY exhibit competitive binding to the kinase CheA, Biochemistry, 34, 14626, 10.1021/bi00045a003
Lieleg, 2011, Mechanical robustness of Pseudomonas aeruginosa biofilms, Soft Matter, 7, 3307, 10.1039/c0sm01467b
Livermore, 2002, Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?, Clin Infect Dis, 34, 634, 10.1086/338782
Lyczak, 2000, Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist, Microbiol Infect, 2, 1051, 10.1016/S1286-4579(00)01259-4
Mah, 2001, Mechanisms of biofilm resistance to antimicrobial agents, Trends Microbiol, 9, 34, 10.1016/S0966-842X(00)01913-2
Malloy, 2005, Pseudomonas aeruginosa protease IV degrades surfactant proteins and inhibits surfactant host defense and biophysical functions, Am J Physiol Lung Cell Mol Physiol, 288, L409, 10.1152/ajplung.00322.2004
Mariencheck, 2003, Pseudomonas aeruginosa elastase degrades surfactant proteins A and D, Am J Respir Cell Mol Biol, 28, 528, 10.1165/rcmb.2002-0141OC
Mathee, 1999, Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung, Microbiology, 145, 1349, 10.1099/13500872-145-6-1349
Mathee, 2008, Dynamics of Pseudomonas aeruginosa genome evolution, P Natl Acad Sci USA, 105, 3100, 10.1073/pnas.0711982105
Matsumoto, 2004, Role of bacterial proteases in pseudomonal and serratial keratitis, Biol Chem, 385, 1007, 10.1515/BC.2004.131
Matsumoto, 1998, Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice, J Med Microbiol, 47, 303, 10.1099/00222615-47-4-303
Matsuo, 2004, MexZ-mediated regulation of mexXY multidrug efflux pump expression in Pseudomonas aeruginosa by binding on the mexZ-mexX intergenic DNA, FEMS Microbiol Lett, 238, 23
McPhee, 2003, Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa, Mol Microbiol, 50, 205, 10.1046/j.1365-2958.2003.03673.x
McPhee, 2006, Contribution of the PhoP-PhoQ and PmrA-PmrB two-component regulatory systems to Mg2+-induced gene regulation in Pseudomonas aeruginosa, J Bacteriol, 188, 3995, 10.1128/JB.00053-06
Mena, 2008, Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation, J Bacteriol, 190, 7910, 10.1128/JB.01147-08
Miao, 2007, TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system, Semin Immunopathol, 29, 275, 10.1007/s00281-007-0078-z
Mikkelsen, 2011, Key two-component regulatory systems that control biofilm formation in Pseudomonas aeruginosa, Environ Microbiol, 13, 1666, 10.1111/j.1462-2920.2011.02495.x
Miller, 2011, PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients, Antimicrob Agents Chemother, 55, 5761, 10.1128/AAC.05391-11
Miyazaki, 1995, Role of exotoxin A in inducing severe Pseudomonas aeruginosa infections in mice, J Med Microbiol, 43, 169, 10.1099/00222615-43-3-169
Moore, 2011, Antimicrobial resistance mechanisms in Pseudomonas aeruginosa, Clin Lab Sci, 24, 47, 10.29074/ascls.24.1.47
Morissette, 1996, Lung phagocyte bactericidal function in strains of mice resistant and susceptible to Pseudomonas aeruginosa, Infect Immun, 64, 4984, 10.1128/IAI.64.12.4984-4992.1996
Moscoso, 2011, The Pseudomonas aeruginosa sensor RetS switches type 3 and type 6 secretion via c-di-GMP signalling, Environ Microbiol, 13, 3128, 10.1111/j.1462-2920.2011.02595.x
Murphy, 2008, Pseudomonas aeruginosa in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 177, 853, 10.1164/rccm.200709-1413OC
Ojielo, 2003, Defective phagocytosis and clearance of Pseudomonas aeruginosa in the lung following bone marrow transplantation, J Immunol, 171, 4416, 10.4049/jimmunol.171.8.4416
Oliver, 2010, Mutators in cystic fibrosis chronic lung infection: prevalence, mechanisms, and consequences for antimicrobial therapy, Int J Med Microbiol, 300, 563, 10.1016/j.ijmm.2010.08.009
Ostroff, 1990, Molecular comparison of a nonhemolytic and a hemolytic phospholipase C from Pseudomonas aeruginosa, J Bacteriol, 172, 5915, 10.1128/jb.172.10.5915-5923.1990
Otter, 2011, The role played by contaminated surfaces in the transmission of nosocomial pathogens, Infect Control Hosp Epidemiol, 32, 687, 10.1086/660363
Pearson, 2000, Pseudomonas aeruginosa cell-to-cell signaling is required for virulence in a model of acute pulmonary infection, Infect Immun, 68, 4331, 10.1128/IAI.68.7.4331-4334.2000
Provinciali, 2011, Inflammation, chronic obstructive pulmonary disease and aging, Curr Opin Pulm Med, 17, S3, 10.1097/01.mcp.0000410742.90463.1f
Ryder, 2007, Role of polysaccharides in Pseudomonas aeruginosa biofilm development, Curr Opin Microbiol, 10, 644, 10.1016/j.mib.2007.09.010
Sadikot, 2005, Pathogen-host interactions in Pseudomonas aeruginosa pneumonia, Am J Respir Crit Care Med, 171, 1209, 10.1164/rccm.200408-1044SO
Schultz, 2000, The effect of Pseudomonas exotoxin A on cytokine production in whole blood exposed to Pseudomonas aeruginosa, FEMS Immunol Med Microbiol, 29, 227, 10.1111/j.1574-695X.2000.tb01527.x
Schweizer, 2003, Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions, Genet Mol Res, 2, 48
Shaver, 2004, Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung, Infect Immun, 72, 6969, 10.1128/IAI.72.12.6969-6977.2004
Silby, 2011, Pseudomonas genomes: diverse and adaptable, FEMS Microbiol Rev, 35, 652, 10.1111/j.1574-6976.2011.00269.x
Smith, 2006, Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients, P Natl Acad Sci USA, 103, 8487, 10.1073/pnas.0602138103
Sriramulu, 2005, Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung, J Med Microbiol, 54, 667, 10.1099/jmm.0.45969-0
Stephenson, 2002, Two-component and phosphorelay signal-transduction systems as therapeutic targets, Curr Opin Pharmacol, 2, 507, 10.1016/S1471-4892(02)00194-7
Stock, 2000, Two-component signal transduction, Annu Rev Biochem, 69, 183, 10.1146/annurev.biochem.69.1.183
Stover, 2000, Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen, Nature, 406, 959, 10.1038/35023079
Strateva, 2009, Pseudomonas aeruginosa - a phenomenon of bacterial resistance, J Med Microbiol, 58, 1133, 10.1099/jmm.0.009142-0
Teghanemt, 2005, Molecular basis of reduced potency of underacylated endotoxins, J Immunol, 175, 4669, 10.4049/jimmunol.175.7.4669
Tingpej, 2007, Phenotypic characterization of clonal and nonclonal Pseudomonas aeruginosa strains isolated from lungs of adults with cystic fibrosis, J Clin Microbiol, 45, 1697, 10.1128/JCM.02364-06
Toder, 1994, lasA and lasB genes of Pseudomonas aeruginosa: analysis of transcription and gene product activity, Infect Immun, 62, 1320, 10.1128/IAI.62.4.1320-1327.1994
Tsai, 2000, CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia, Infect Immun, 68, 4289, 10.1128/IAI.68.7.4289-4296.2000
Veesenmeyer, 2009, Pseudomonas aeruginosa virulence and therapy: evolving translational strategies, Crit Care Med, 37, 1777, 10.1097/CCM.0b013e31819ff137
Vinckx, 2010, The Pseudomonas aeruginosa oxidative stress regulator OxyR influences production of pyocyanin and rhamnolipids: protective role of pyocyanin, Microbiology, 156, 678, 10.1099/mic.0.031971-0
Waite, 2006, Clustering of Pseudomonas aeruginosa transcriptomes from planktonic cultures, developing and mature biofilms reveals distinct expression profiles, BMC Genomics, 7, 162, 10.1186/1471-2164-7-162
Whitsett, 2002, Intrinsic and innate defenses in the lung: intersection of pathways regulating lung morphogenesis, host defense, and repair, J Clin Invest, 109, 565, 10.1172/JCI0215209
Williams, 2007, Colonic neutrophils in inflammatory bowel disease: double-edged swords of the innate immune system with protective and destructive capacity, Gastroenterology, 133, 2049, 10.1053/j.gastro.2007.10.031
Williams, 2010, Pseudomonas aeruginosa: host defence in lung diseases, Respirology, 15, 1037, 10.1111/j.1440-1843.2010.01819.x
Winsor, 2005, Pseudomonas aeruginosa Genome Database and PseudoCAP: facilitating community-based, continually updated, genome annotation, Nucleic Acids Res, 33, D338, 10.1093/nar/gki047
Winstanley, 2009, The role of quorum sensing in chronic cystic fibrosis Pseudomonas aeruginosa infections, FEMS Microbiol Lett, 290, 1, 10.1111/j.1574-6968.2008.01394.x
Wolf, 2009, Pseudomonas exotoxin A: from virulence factor to anti-cancer agent International, J Med Microbiol, 299, 161, 10.1016/j.ijmm.2008.08.003
Wolfgang, 2004, Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients, P Natl Acad Sci USA, 101, 6664, 10.1073/pnas.0307553101
Wozniak, 2003, Alginate is not a significant component of the extracellular polysaccharide matrix of PA14 and PAO1 Pseudomonas aeruginosa biofilms, P Natl Acad Sci USA, 100, 7907, 10.1073/pnas.1231792100
Yahr, 2006, Transcriptional regulation of the Pseudomonas aeruginosa type 3 secretion system, Mol Microbiol, 62, 631, 10.1111/j.1365-2958.2006.05412.x